Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.
about
Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expressionMethodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical reviewSystemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateFeasibility study of adjuvant chemotherapy of S-1 and carboplatin for completely resected non-small cell lung cancer.Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer.Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001.Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.Protein and mRNA expression of folic acid-associated enzymes as biomarkers for the cytotoxicity of the thymidylate synthase-targeted drugs, pemetrexed and S-1, in non-small cell lung cancerComparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinomaEligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study.New challenges and inspired answers for anticancer drug discovery and developmentFavorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studiesCyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.Phase II Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment.A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.Differences in the efficacy of S-1 monotherapy according to histological type in pretreated patients with advanced non-small cell lung cancer.A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC).S-1-containing chemotherapy for patients with non-small-cell lung cancer: A population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group.Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0Successful chemotherapy with Carboplatin and s-1 for thymic carcinoma: a case report.Outcome of platinum-based chemotherapy for non-small-cell lung cancer patients with pleural dissemination detected during surgery.The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer.Feasibility of adjuvant chemotherapy with S-1 consisting of a 4-week administration and a two-week rest period in patients with completely resected non-small cell lung cancer.Thymidylate synthase inhibitors for non-small cell lung cancer.Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective.Efficacy of S-1 in non-small cell lung cancer.Implementation of modern therapy approaches and research for non-small cell lung cancer in Japan.S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.S-1-based regimens for locally advanced/metastatic non-small-cell lung cancer: a meta-analysis.Novel therapies for advanced squamous cell carcinoma of the lung.S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model.Bayesian population finding with biomarkers in a randomized clinical trial.Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.Prospective exploratory study of gemcitabine and S-1 against elderly patients with advanced non-small cell lung cancerAdherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial.Expression of thymidylate synthase predicts clinical outcomes of S-1-based chemotherapy in squamous cell lung cancer
P2860
Q26747641-298E44E5-C8A8-4D8E-8596-18C76215CA93Q28068435-6F9EA0B1-8A91-4317-9130-7D6B79351B52Q30356434-CF7612C6-D012-44E7-B2AB-865742A70C9BQ33408830-1AD48D34-19EE-46A0-9BE8-F563D72B1885Q33419961-077A0C84-590C-476A-BC36-D3C7734DA97FQ33432898-68467BB3-90DB-46B3-BDD5-DC8F989D1580Q33437409-E01CA8DC-C85A-430E-A3EB-0169AC1B3CCAQ33441606-6048D568-EA84-4CA7-8BB8-9171C41A3BA5Q33688612-88AF6CA0-2BA5-4A2D-AF3F-634FC39287B0Q33857989-90A0DFEC-4535-4FA6-880C-6A33520BF6DEQ33913820-67BFAAB7-4AF7-41A2-8DD0-26CE1980B724Q34651916-AEB5ECB2-206A-431F-9387-BE2084A301F9Q34981175-F1BB6E2F-62EE-4C45-B86A-B1495C9C566FQ35073353-B6695442-89E1-4B85-9492-4D5DB9590FADQ35096604-CA226B6B-2AE7-415B-8B9C-4209A4CDBD38Q35661045-D5653F23-0F44-4E38-9D17-3BAE5CFBD1FCQ35678690-5EA0D5B5-74E4-482C-B671-DF5CD0FDA812Q35742451-F30570FA-601A-4CAE-BCF5-7EDF1887AC3BQ35775244-E6A79387-1482-4167-A3A6-0DE341E5A803Q36439382-A9B6456C-CA9A-415A-8E09-922C12E5DE66Q36547234-5CF2190C-81DC-4F01-8B2C-1BFB1CC767C2Q36953416-25246F9E-9BE2-4F20-9430-D65BF416C60DQ37081978-0A53BBBB-EA7B-455B-A918-BA7837AF797BQ37350805-12E2CB6B-4DCC-48F0-A625-A464677AA2CCQ37560778-CB950172-1F39-49A6-B9E9-6BA9ACC46131Q37603638-34C5E28B-366A-4A1E-8919-2D0A0B7D5A2DQ37641034-D74239F3-F5C1-4CB7-A782-A4E2F9FF93F8Q37929783-B87B926E-F7EA-48EF-AB39-F5CAB01C770EQ38133562-0ABAA1FE-A5B7-4DBF-B4A9-E49C56B086A7Q38238511-2A1689DB-47B8-4AB6-9A31-BEFCBEF181BFQ38320914-FA05313A-3B68-4B00-8294-B22FA0232348Q38619215-E69AF9D4-9C62-4BFB-8DF8-8541BFF3968FQ38720596-99CD449A-A584-4F7E-8C5D-C892E955779AQ38734978-9E4EC46C-C7CF-446C-899F-71FDB140510EQ38776511-12537A2A-3C9D-43A6-B9BF-8868238BEE7EQ38931091-1FF93027-6F16-4DF7-9314-2DE0137F30CDQ39808352-B23560F6-4618-4A61-A361-60F82F586292Q40979235-D4C2B080-22D6-4679-ADE2-E81E33625ADBQ41554812-501AEE55-E37A-447B-859E-92CB00DDACB9Q41620291-BA400219-D016-46F3-9C32-469CB01AF3E1
P2860
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase III trial comparing oral ...... st Japan oncology group study.
@ast
Phase III trial comparing oral ...... st Japan oncology group study.
@en
type
label
Phase III trial comparing oral ...... st Japan oncology group study.
@ast
Phase III trial comparing oral ...... st Japan oncology group study.
@en
prefLabel
Phase III trial comparing oral ...... st Japan oncology group study.
@ast
Phase III trial comparing oral ...... st Japan oncology group study.
@en
P2093
P356
P1476
Phase III trial comparing oral ...... st Japan oncology group study.
@en
P2093
Hideo Saka
Hiroshige Yoshioka
Isamu Okamoto
Kazuhiko Nakagawa
Kazuhiro Asami
Kenji Tamura
Koji Takeda
Masahiko Ando
Masahiro Fukuoka
Masaki Miyazaki
P304
P356
10.1200/JCO.2010.31.0326
P407
P50
P577
2010-11-15T00:00:00Z